


PHARMACEUTICAL 2017

XBiotech Inc. Rank 114 of 292









PHARMACEUTICAL 2017

XBiotech Inc. Rank 114 of 292



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 58% points. The greatest weakness of XBiotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 125% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	36,930
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,963
Liabilities, Non-Current	0
Other Assets	19,978
Other Compr. Net Income	-1,781
Other Expenses	0
Other Liabilities	23
Other Net Income	2.0
Other Revenues	0
Property and Equipment	10,142
Research and Development	42,486
Selling, General and Administrative Expense	10,277

Output Variable	Value in 1000 USD
Assets	67,050
Liabilities	7,986
Expenses	52,763
Revenues	0
Stockholders Equity	59,064
Net Income	-52,761
Comprehensive Net Income	-53,652
Economic Capital Ratio	128%

